



Building Successful China Medtech Market Entry Strategies

January 24, 2024

Hamish King, CEO at Cisema | hamish.king@cisema.com | www.cisema.com





Part 1: Cisema presentation on Regulatory Strategy



About Cisema



Regulatory affairs, quality assurance, clinical research, product testing & safety certification services for China & Hong Kong

- Experienced **in-house and full-time team** of local, on-the-ground regulatory affairs & quality compliance specialists in our China offices.
- Adding value by accelerating your time to market in a cost-efficient, planned, strategic way. We do the work, so you can focus on your core business.
- Ensure you **maintain control** of your product registrations and retain unconstrained choice of distributor(s).
- Provide full-cost quotation from the beginning of the project, giving price transparency and clarity for budgeting and planning

20 years' experience

Sectors:

- Medical devices & IVDs
- Pharmaceuticals
- Cosmetics
- Health foods & supplements
- Industrial goods
- Consumer goods



100 employees worldwide | 12 offices




- Recent trends
- Regulatory partnerships and pathways to achieve success in the market
- Key challenges
- Timeline & costs
- Is China localization required to compete?

Top tips

Registration Trends: NMPA Approvals in 2022




• NMPA handles applications and approvals for Domestic Class III and all overseas approvals






5218 Registration Renewals (43.7%)

4224 Changes in Licensing Item (35.4%)



Registration Trends: NMPA New Approvals over time








2020	2021	2022
1. Dental Instruments	1. Medical Imaging Equipment	1. Medical Imaging Equipment
2. Medical Imaging Equipment	2. Passive Implantable Devices	2. Passive Implantable Devices
3. Passive Implantable Devices	3. Dental Instruments	3. Infusion, Nursing & Protective Equipment
4. Neurological & Cardiovascular Surgical Instruments	4. Neurological & Cardiovascular Surgical Instruments	4. Dental Instruments
5. Ophthalmic Devices	5. Ophthalmic Devices	5. Neurological & Cardiovascular Surgical Instruments

Pathways to register medical devices in China


Mainland China

Alternative pathways

Cisema








• If they are complete and meet the formal requirements, the certificate for the filing with NMPA stamp will be issued immediately.

Class II & III Registration Process





Expected registration time frame: About 18 months for class II and 21 months for class III without clinical trials


Costs and timelines for standard process



- Application fee payable upon submission for new NMPA medical device or IVD filing/registration:
 - Class I: ¥ 0
 - Class II: ~USD30,000 (¥ 210,900)
 - Class III: ~USD44,000 (¥ 308,800)
- Timelines according to experience:
 - Class I: ~4 months
 - Class II: ~18 months
 - Class III: ~21 months

- Additional fees to take into consideration:
 - Type tests
 - Importation
 - Notarization
 - Translation





Is China 'localization' required to compete?

- Cisema
- For high-end medical devices, foreign companies remain as dominating market players in China.
- Headwinds:
 - Buy "Made in China" & localization trends
 - Bidding platform practical difficulties
- Tender bidding platform operation -> despite their insistence, not necessary for distributor to be local agent.

Options to localize production in China



Market Authorization Holder (MAH)

- Establish own entity in China to act as MAH
- Find Chinese partner as OEM
- OEM produces samples
- Local registration of MD (certificate transfer)
- MAH receives product approval & sales license
- OEM starts to produce
- MAH starts to sell

Wholly foreign-owned enterprise (WFOE)

- Find location for factory
- Create WFOE and build factory
- Produce samples

VS

- Local registration of MD (certificate transfer)
- WFOE receives product approval and sales license
- WFOE starts to produce and sell

Hong Kong Listing

- Voluntary system for product safety approvals of medical devices and IVDs
- Advantages to listing your product for tender wins and market adoption
 - Source: <u>New Procurement Requirement of the Department of Health for Medical Devices</u>
- Law changes on the horizon that may make listing mandatory

Key points:

- Require a Local Responsible Person (LRP) in Hong Kong
- Classification of product according to Hong Kong standards
- Submission dossier for listing with the Hong Kong Medical Device Administrative Control System (MDACS)
- Post-approval requirements
- Enables subsequent Greater Bay Area applications and registration
- Real-world data for eventual Mainland China registration





Top Tips



- Start regulatory and feasibility discussions early
- Evaluate the various pathways to market
- Understand in-China testing requirements:
 - 1. Conduct internal validation tests in advance according to Chinese testing standards
 - 2. Consider whether education on product usage possible for test lab consultant, if relevant
- Don't treat China like just another export market
- Don't rely on your distributor only
- Think long-term and stay objective

Cisema Services Overview for MedTech in China



Pre-Registration	Registration	Post-Registration
 Regulatory Pathway Feasibility Studies Clinical Trial Protocol Design CRO China Clinical Trials 	 NMPA Legal Agent NMPA Filing of Class I NMPA Registration of Class II & III incl. CER writing Hong Kong Listing Type Testing Support 	 Post-Market Surveillance Advise on "Made in China" minimum production step Analysis of MAH vs OEM pathways for localization Overseas factory inspections
	 Labelling Support 	 GMP, QMS, SOP adaptation

- Certificate localization in China
- China audits

Cisema around the World





Follow up whitepaper or other information available by email or website request: <u>https://www.cisema.com/en/knowledge/free-know-how/</u>





Hamish King CEO T: +852 6468 6239 E: hamish.king@cisema.com

